Login to Your Account



Treatment Paradigm Could Change

Pfizer's JAK Inhibitor Xeljanz Approved, Set to Launch in RA

By Marie Powers
Staff Writer

Thursday, November 8, 2012

Pfizer Inc. is wasting no time with the rollout of its Janus kinase (JAK) inhibitor tofacitinib, branded Xeljanz, which gained FDA approval late Tuesday for adults with moderate to severely active rheumatoid arthritis (RA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription